Farid Jadbabaie, MD
Cardiovascular Disease · New Haven, CTNPI 1245213677
Payments from drug & device makers
What this record shows
Novartis accounts for 68.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $1,224 and has fallen 74.9% since, to $307 in 2025.
Across 25 payments — averaging $71.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boston Scientific$412
- Impulse Dynamics (USA) Inc.$161
Across 16 payments — averaging $11,177 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$123K
- Amgen$56K
What the payments were for
- Travel & lodging$87649%
- Food & beverage$92151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $1,224 |
| Boston Scientific | 17 | $412 |
| Impulse Dynamics (USA) Inc. | 1 | $161 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,797 in reported general payments places this provider in the 55th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New Haven
- Nihar DesaiNew Haven$1.4M
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Cesia Maria Gallegos KattanNew Haven$101K
- Khurram NasirNew Haven$100K
- Tariq AhmadNew Haven$75K
- Joseph AkarNew Haven$74K
- Hyung ChunNew Haven$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.